Brain Imaging and Retreatment Study of Persistent Lyme Disease

This study has been completed.
Sponsor:
Information provided by:
National Institute of Neurological Disorders and Stroke (NINDS)
ClinicalTrials.gov Identifier:
NCT00037479
First received: May 17, 2002
Last updated: December 6, 2005
Last verified: December 2005

May 17, 2002
December 6, 2005
December 1999
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00037479 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Brain Imaging and Retreatment Study of Persistent Lyme Disease
PET and MRI Imaging of Persistent Lyme Encephalopathy

The purpose of this study is to determine whether patients with persistent memory problems after Lyme disease benefit from an additional longer course of IV antibiotic therapy; to use modern brain imaging technology to determine whether the problem in the central nervous system is primarily one of poor blood flow or one of impaired nerve cell functioning; and to try to identify biological markers prior to treatment that will identify patients who are more or less likely to respond to the study treatment.

Some people with a history of Lyme disease continue to have problems despite having received “textbook duration” antibiotic therapy. When memory, attention, or thinking problems persist, the syndrome is called persistent Lyme disease (PLD). This study seeks to answer critical scientific questions about the treatment and cause of PLD symptoms.

This 24-week treatment study will evaluate each patient’s response to treatment using neuropsychological testing and state-of-the-art brain imaging. The brain tests include neuropsychological testing of memory and attention, brain imaging (MRI and PET scans) to look at blood flow in the brain and nerve cell structure and metabolism, a neurological exam, and studies of the fluid that surrounds the brain (cerebrospinal fluid). The treatment involves 10 weeks of either intravenous antibiotic called ceftriaxone (also known as Rocephin) or intravenous placebo (inactive substance). After the first visit to Columbia Presbyterian Medical Center, the remaining treatments will be done in the patient’s home. Patients will be screened over the phone and in person to confirm study eligibility.

Interventional
Phase 2
Allocation: Randomized
Primary Purpose: Treatment
  • Lyme Disease
  • Lyme Neuroborreliosis
Drug: ceftriaxone
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
65
Not Provided
Not Provided

Inclusion Criteria:

Eligible participants must:

  • Be 18-65 years old
  • Have persistent problems with memory, verbal fluency, or attention after having contracted Lyme disease.
  • Be able to travel to New York for 4-5 evaluations over the course of one year. Travel costs for participants in need may be partially or fully reimbursable.
  • Have had a history of well-documented Lyme disease using the CDC's clinical criteria and a current positive IgG Western blot or PCR.
  • Have received, at some point in the past at least 3 weeks of IV antibiotic therapy for Lyme disease.

Exclusion Criteria:

Ineligible from participation are people with the following:

  • Other major medical or neurologic problems
  • Smoke more than 10 cigarettes a day
  • Uncontrolled high blood pressure
  • Allergy to ceftriaxone (Rocephin)
  • History of marked cocaine abuse

Twenty healthy subjects are also being sought for the study.

Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00037479
R01NS38636
Not Provided
Not Provided
National Institute of Neurological Disorders and Stroke (NINDS)
Not Provided
Principal Investigator: Brian Fallon, M.D. Columbia University, College of Physicians and Surgeons, Lyme Disease Research Program
National Institute of Neurological Disorders and Stroke (NINDS)
December 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP